|
| Bacteriocins -classification | Producing bacteria | Target organism | Mode of action | Model | Security |
|
| Nisin lanthipeptide [17, 103–105] | L. lactis | S. aureus, C. difficile | Lipid II binding and pore formation | In vitro, mice and rats (intraperitoneal injection and nasal administration) | FDA approved and generally regarded as safe |
| NAI-107 lanthipeptide [106, 107] | Microbispora sp. | S. aureus | Inhibits the synthesis of peptidoglycan | In vitro and mice (intravenous and subcutaneous administration) | Low acute toxicity |
| Mutacin B-Ny266 lanthipeptide [108, 109] | S. mutans | S. aureus, Neisseria Helicobacter | Unknown | In vitro and mice (intraperitoneal injection) | Not evaluated |
| OG716 lanthipeptide [110] | S. mutans JH1140 | C. difficile | Binding the pyrophosphate moiety of lipid-II | In vitro and hamster | Low toxicity |
| Mersacidin lanthipeptide [22, 111–113] | Bacillus sp. HIL-Y85/54728 | MRSA | Inhibits bacterial cell wall biosynthesis by complexing lipid II | In vitro and mice (nasal administration and subcutaneously administered) | Not evaluated |
| Actagardine A lanthipeptide [114] | A. garbadinensis ATCC 31049 | C. difficile, VRE MRSA | Inhibits cell wall biosynthesis by binding to lipid II and blocking transglycosylation | In vitro | Not evaluated |
| NVB302 lanthipeptide [115, 116] | Derivative of deoxyactagardine B from A. liguriae | C. difficile | Binding to lipid II | In vitro and hamsters (oral gavage) and ex vivo gut model | Nontoxic |
| NVB333 lanthipeptide [117] | S.aureus | In vitro and mice (i.v. injection) | No signs of any drug-related adverse effects |
| Lacticin 3147 lanthipeptide [118] | L. lactis DPC3147 | C. difficile, L. monocytogenes | Binding to lipid II and lytic | In vitro | Not evaluated |
| Lassomycin class I-lasso peptide [119] | Lentzea kentuckyensis | M. tuberculosis | Target the ATP-dependent protease | In vitro | Not evaluated |
| Microcin J25 lasso peptide [26, 80, 120, 121] | E. coli | Salmonella, E. coli | Inhibiting RNA polymerase and increasing superoxide production | In vitro and mice | No cytotoxicity |
| Enterocin AS-48 head-to-tail cyclized peptides [122–125] | E. faecalis | M. tuberculosis | Accumulating a positive charge on the membrane surface and disrupts the membrane potential | In vitro and macrophages | No cytotoxicity |
| Thiostrepton thiopeptide [126, 127] | Streptomyces sp. | M. abscessus | Binding to a site on 23S rRNA and inhibits elongation factor-dependent reactions | In vitro, zebrafish and macrophages | US FDA-approved drug |
| Durancin 61A glycosylated bacteriocin [128, 129] | E. durans 61A | C. difficile, VRE, MRSA, L. innocua | Targeting the bacterial membrane | In vitro | Not hemolytic |
| Thuricin CD sactipeptide [87, 130, 131] | B. thuringiensis DPC 6431 | C. difficile, L. monocytogenes | Permeabilize and depolarize the membrane | In vitro and mice | Not evaluated |
| Ruminococcin C sactipeptide [132, 133] | R. gnavus E1 | Pathogenic clostridia and MDR strains | Inhibiting nucleic acid synthesis in a metronidazole-like manner | In vitro | Not toxic to eukaryotic cells |
| Gassericin E head-to-tail cyclized peptides [30] | L. gasseri EV1461 | Multiple pathogens associated with bacterial vaginosis | Unknow | In vitro | Not evaluated |
| Microcin H47 [134] | E. coli Nissle 1917 | E. coli | Targeting the F0 proton channel of ATP synthase | In vitro | Not evaluated |
| Microcin E492 [135] | K. pneumoniae RYC492 | K. Enterobacter E. coli Salmonella sp. | Permeabilize the inner membrane with the mannose permease | In vitro | Induces apoptosis in some human cell lines |
| Microcin M [136] | E. coli Nissle 1917 | E. coli Salmonella sp. | Compete against other enterobacteria that utilize catecholate siderophores | In vitro | Not evaluated |
| Lactocin 160 [137, 138] | L. Rhamnosus | G. Vaginalis
Bacillus pertussis | Causing the efflux of ATP molecules and dissipative the proton motive force | In epivaginal | Minimal irritation |
| Enterocin CRL35 class IIa [25, 139] | E. mundtii | L. monocytogenes | Forming holes in the cell wall and cell membrane | In vitro and mice (orally administrated) | Not evaluated |
| Lactocin AL705 class IIa [140, 141] | L. curvatus | L. monocytogenes | Disrupting quorum sensing through a signal molecule inactivation | In vitro | Not evaluated |
| Pediocin PA-1 class IIa [24, 142, 143] | P. acidilactici | L. monocytogenes | Forms hydrophilic pores in the cytoplasmic membrane | In intra-gastric administration | Commercial applications with no adverse effect |
Laterosporulin10
class IId [21] | B. laterosporus SKDU10 | S. aureus, M. smegmatis | Membrane permeabilization | In vitro and macrophages | No hemolytic activity |
| Subtilosin class II [29, 144, 145] | B. subtilis | G. vaginali, L. monocytogenes, S. agalactiae | Binding to lipid bilayers, results in membrane permeabilization | In epivaginal | Human cells remained viable after prolonged exposures to subtilosin |
| Colicin Z class III [27] | E. coli B1356 | E. coli Shigella | Via cjrc receptor recognition and cjrb- and exbb- and exbd-mediated colicin translocation | In vitro | Not evaluated |
| Colicin F Y class III [28, 146] | E. coli | Y. enterocolitica | Yiur-mediated reception, tonb import, and cell membrane pore formation | In mice | Not evaluated |
| Diffocin class III [102, 147] | C. difficile CD4 | C. difficile | Dissipating the membrane potential | In vitro and mice | Not evaluated |
| ESL5 [148] | E. faecalis SL-5 | P. acnes | Unknown | In vitro and human | Not evaluated |
| Bacteriocin OR-7 [149] | L. salivarius NRRL B-30514 | C. jejuni | Unknown | In chicken | Not evaluated |
| Bacteriocin E 50-52 class IIa [150] | E. faecium NRRL B-30746 | S. enteritidis | Unknown | In chicken | Not evaluated |
| Subtilosin class II [37] | B. subtilis | HSV-1 and HSV-2 | Inhibiting virus multiplication | In vitro | Human cells remained viable after prolonged exposures to subtilosin |
| Labyrinthopeptin A1 lanthipeptide [40, 41, 151] | A. namibiensis DSM 6313 | HSV, HIV, zika virus, and dengue virus | Acting as an entry inhibitor possibly by targeting the HSV glycoproteins | In vitro | Does not harm the vaginal epithelium or the normal vaginal lactic acid flora |
| Enterocin CRL35 class IIa [38, 39] | E. mundtii | HSV-1 and HSV-2 | Affecting a late step of virus multiplication | In vitro | Low cytotoxicity for eukaryotic cells |
| Mundticin ST4SA class IIa [42] | E. mundtii ST4V | HSV-1, HSV-2, poliovirus and measles virus | Unknown | In vitro | Not evaluated |
| Enterocin AS-48 class I-head-to-tail cyclized peptides [48, 125, 152] | E. faecalis | Trypanosoma cruzi | Mitochondrial membrane depolarization and reactive oxygen species production | In vitro and mice | No cytotoxicity |
| Addlp class II [49] | A. dehalogenans | Plasmodium falciparum | Unknown | In vitro | Nontoxic to mammalian cells |
|
